Used in pharmaceutical research as a key intermediate in the synthesis of proteolysis-targeting chimeras (PROTACs). It functions as a linker component that connects a target protein binder to an E3 ubiquitin ligase recruiter, enabling targeted degradation of disease-related proteins. Its structure supports enhanced cell permeability and stability, making it suitable for developing degraders in oncology and neurodegenerative disease studies. The compound's piperazine and fluorinated aryl groups contribute to favorable binding kinetics and pharmacokinetic properties in preclinical models.